Author: admin

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib – Rituximab Combination for Relapsed CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Idelalisib + Ofatumumab as First Line Therapy for Patients with CLL at ASH 2015

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning in CLL

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Redistribution Lymphocytosis in CLL

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Utilizing Idelalisb and Ibrutinib in CLL at ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai talks about Combining Antibody TherapyWith BTK Inhibitor in Folicular Lymphoma at ASH 2015

Press brief by Mark C. Walters, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Walters provides an update on the Northstar study of subjects treated with the LentiGlobin BB305 Drug Product. Previously reported early results in subjects with ?-thalassemia major participating in the ongoing HGB-205 and HGB-204 (Northstar) studies suggest that transplantation with autologous CD34+ cells transduced with a replication-defective, self-inactivating LentiGlobin BB305 lentiviral vector containing an engineered ?A-T87Q?globin gene (LentiGlobin BB305 Drug Product) has a positive safety profile and leads to ?A-T87Qglobin production and can lead to transfusion independence.

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses Chimeric Antigen Receptor T-Cells from ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives an Update of Combining Immunotherapy with Targeted Therapies an Update from ASH 2015

Dr. Joshua Brody, MD @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai gives and update on Checkpoint Blockade from ASH 2015

Dr. Joshua Brody, MD – @joshuabrodyMD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai discusses an update on BCR signaling inhibitors in CLL at ASH 2015

Press brief by James N. Kochenderfer, MD, at the American Socitety of Hematology (ASH) 2015 annual meeting. Dr Kochenderfer provides an overview of a trial of allogeneic T-cells that were genetically engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit of the modified UKONS telephone triage tool that has been implemented for the Acute Oncology Service at The Royal Marsden Hospital. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Join us for a provocative program format that includes point and counterpoint presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma. Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma.

Dr. Morie Gertz of the Mayo Clinic shares his overview of this year’s American Society of Hematology (ASH) meeting. He talks about Dr. Brian Durie’s discussion of three-drug treatment providing longer overall survival in newly diagnosed multiple myeloma patients versus two-drug treatment. He also discusses the recent advances in oral agents to treat multiple myeloma.

Dr. Sagar Lonial of the Winship Cancer Institute of Emory University in Atlanta, Georgia, speaks from the American Society of Hematology’s (ASH) national conference this weekend. In this video, Dr. Lonial discusses the excitement at ASH about two-drug versus three-drug treatment approaches in newly diagnosed myeloma patients.

Dr. Kenneth Anderson of the Dana-Farber Cancer Institute and Vice President of the American Society for Hematology (ASH) shares about the exciting advances being discussed at the ASH annual conference this weekend in Orlando, Florida.

Dr. Saad Usmani of the Levine Cancer Institute in Charlotte, North Carolina, gives his perspective on the treatment options for newly diagnosed as well as relapsed/refractory multiple myeloma patients, as discussed this weekend at the American Society of Hematology (ASH) annual conference in Orlando, Florida.

Dr. Meletios Dimopoulus provides an update on the Eloquent-2 Trial: A Phase 3 Randomized, Open-Label Study of elotuzumab in Combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma. Dr. Meletios Dimopoulos National and Kapodistrian University of Athens School of Medicine Athens, Greece Elotuzumab is an immunostimulatory monoclonal antibody (mAb) that recognizes Signaling Lymphocytic Activation Molecule F7 (SLAMF7), a protein highly expressed by myeloma and natural killer cells. Elotuzumab has a dual mechanism of action, directly activating natural killer cells and initiating antibody-dependent cell-mediated cytotoxicity targeted against myeloma cells, with minimal effect on normal tissues. In the 2-year progression-free survival (PFS)…

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Toby Talbot, MB BS, of Royal Cornwall Hospitals NHS Trust, Truro, UK, reviews the advances in cancer immunotherapeutic approaches, highlighting the development of the anti-CTLA4 monoclonal antibody, ipilimumab, for the treatment of metastatic melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Saad Usmani reports on the clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis – a Matched Case Control Study Dr. Ashutosh Wechalekar National Amyloidosis Centre University College London London, United Kingdom Survival of patients with cardiac AL amyloidosis remains poor due to high mortality in the first 6-12 months. Rapidly effective regimes such as CyBorD are unable to overcome poor prognosis in very advanced AL amyloidosis (Venner et al and Palladini et al Leukemia 2014). The median survival of moderately advanced AL is ~60% at 2 years with CyBorD (Palladini et al Blood 2015). Last year, we reported a small series suggesting that oral…

Richard Henry, President Elect of the United Kingdom Oncology Nursing Society (UKONS), and Teaching Fellow at the School of Nursing and Midwifery, Queen’s University Belfast, Belfast, UK, discusses the overarching theme of patient safety and the subsidiary topic of haemato-oncology nursing at the UKONS Annual Conference 2015. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Tim Anstiss, MB, MEd, D.Occ.Med, MFSEM, of the Academy for Health Coaching, explains the concept of motivational interviewing as an approach for clinicians to communicate with patients. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Damian Green of Seattle Cancer Care Alliance presented at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discuses three new treatment options available for patients with multiple myeloma, and the role that clinical trials played in discovery of the new options.

Dr. Ryan Cassaday of Seattle Cancer Care Alliance presented a poster at the 2015 ASH Annual Meeting in Orlando. In the following SCCA video, he discusses how a treatment called hyperCVAD is making a difference for patients with ALL.

Myeloma UK provides information and support for individuals affected by multiple myeloma. At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Monica Morris, Healthcare Professional Programme Manager at Myeloma UK, Edinburgh, UK, discusses Myeloma UKs Myeloma Academy, which is an interactive learning platform designed to provide continuing professional development opportunities for multiple myeloma healthcare professionals in order to support optimal patient care. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Richard Berman, MBBS, MRCGP, FRCP, of The Christie NHS Foundation Trust, Manchester, UK, discusses the recent progress, including the development of 5-HT3 and neurokinin-1 receptor antagonists as potential pharmacologic treatment options, in the management of chemotherapy-induced nausea and vomiting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two do not always correlate, as they can be based on separate biological mechanisms. A patient at high risk of recurrence does not inherently imply that patient will respond to a particular therapy.

At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Rihannon Skilton, Head of Support Line Services, Tenovus Cancer Care, Cardiff, Wales, discusses the ManVan initiative, which is the first dedicated mobile support service for men with prostate, testicular or penile cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Somatic Profiles – NGS Testing

MPN expert Dr. Rami S. Komrokji, Clinical Director of the Malignant Hematology Department at the Moffitt Cancer Center, shares his perspective on the future of research for myeloproliferative neoplasms, new medications and clinical trials. Dr. Komrokji explains how research, past and current, is pushing MPNs closer to becoming a chronic disease. He discusses both existing and new drug therapies and clarifies patient benefits when considering a clinical trial. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

The second monoclonal antibody for myeloma, elotuzumab (Empliciti) was approved today by the U.S. Food and Drug Administration for use in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Patient Power Founder Andrew Schorr caught with patient #1 in the elotuzumab trial, Jay Carty, to get his thoughts on the approval and his perspective on the future of myeloma treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

As part of our Ask the Expert series, MPN expert Dr. Jamile Shammo of Rush University Medical Center responds to a Patient Power community members question, What do we know about ET and PV progression to myelofibrosis? Are there any ways progression can be slowed down? What research is being done in this area? Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

@OncEd Presents Dr. Barb Melosky – Best of Lung Cancer – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Winson Cheung – Best of Health Services / Survivorship – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Scott North – Best of Prostate – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Christian Kollmannsberger – Best of Non-Prostate – best of ASCO 2015 Vancouver

@OncEd Presents Dr. Stephen Chia – Best of Breast Cancer – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Michael Smylie – Best of Melanoma – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Howard Lim – Best of Non-Colorectal – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Sharlene Gill – Best of Colorectal – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Kerry Savage – Bet of Lymphoma – Best of ASCO 2015 Vancouver

@OncEd Presents Dr. Cheryl Ho – Best of Head and Neck – Best of ASCO 2015 Vancouver

@OncEd Presents Pancreatic Tumour Board – 2015

@OncEd Presents Dr. Allan Covens – BRCA Mutations in Ovarian Cancer – 2015

@OncEd Presents Dr. Scott Berry – First Line treatment of Unresectable Metastatic Colorectal Cancer – 2015

@OncEd Presents Dr. Natasha Leighl – Best of Lung Cancer – Best of ASCO 2015 Toronto

@OncEd Presents Dr. Martina Trinkaus – Best of Hematology – Best of ASCO 2015 Toronto